Aura Biosciences Q3 Loss Widens to $32.1M on bel-sar Phase 3 Costs

Aura Biosciences, Inc. (NASDAQ: AURA) reported a net loss of $32.1 million for the third quarter ended September 30, 2026, the clinical-stage biotech announced on November 9, 2026, widening from a $26.1 million loss in the same quarter a year earlier. Research and development expenses rose to $24.7 million from $22.2 million, while general and administrative costs jumped to $10.3 million from $5.7 million. The company ended the quarter with $297.2 million in cash, cash equivalents and marketable securities, which it said funds operations into the first half of 2029.

Context — why Aura's widening loss matters now

The loss expansion is not a surprise for a company funding a global Phase 3 registration trial. Aura's bel-sar program, known as belzupacap sarotalocan, targets early choroidal melanoma, the most common primary tumor of the eye, which the company said carries an approximately 50% risk of advancing to metastatic disease.

The CoMpass trial enrolled 108 participants and, as of the third quarter, all had completed their treatment regimen. They are now in a 24-month follow-up observation period. Topline data from the 15-month primary endpoint is expected in the second half of 2027, the company said.

The trial operates under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration. Aura said the SPA represents alignment with the FDA on trial design and planned analyses to support a potential Biologics License Application. If successful, bel-sar would be the first approved front-line vision-preserving therapy for early choroidal melanoma, a setting where no FDA-approved drug therapies currently exist.

What changed this quarter was the cost structure. Aura recorded approximately $4.5 million in restructuring charges tied to an organizational restructuring to align resources behind its ocular oncology portfolio. Those charges included severance, continued health benefits, outplacement services and accelerated stock-based compensation from vesting of certain awards. The plan was completed in the third quarter of 2026.

The company also established a supply relationship with an industry-leading contract development and manufacturing organization with commercial experience in viral vector-based medicinal products. Aura said it and the CDMO partner are establishing manufacturing capacity designated for bel-sar development and commercial supply production.

Data — what the numbers show

The headline figures come from Aura's condensed consolidated statements. The table below sets the third quarter against the prior-year quarter and the nine-month periods.

Metric	Q3 2026	Q3 2025	9M 2026	9M 2025
Research and development	$24.7M	$22.2M	$83.5M	$68.4M
General and administrative	$10.3M	$5.7M	$34.5M	$17.2M
Total operating expenses	$35.1M	$27.9M	$118.0M	$85.6M
Net loss	$32.1M	$26.1M	$111.4M	$80.6M
Net loss per share	$0.29	$0.40	$1.22	$1.39

Interest income rose to $3.0 million in the quarter from $1.8 million a year earlier, reflecting a larger securities balance. Total other income reached $3.0 million versus $1.8 million.

The balance sheet shows cash and cash equivalents of $41.7 million plus marketable securities of $255.6 million, for the $297.2 million total. That compares with $59.5 million in cash and $84.7 million in marketable securities at December 31, 2025, a combined $144.2 million.

Total assets grew to $321.6 million from $169.4 million. Total stockholders' equity reached $287.4 million, up from $136.9 million, reflecting capital raised during the period. The company also reported treasury stock of 6,922,870 shares held at cost of $39.1 million, versus none at year-end 2025.

Net loss per share narrowed year over year despite the larger absolute loss, because weighted average shares outstanding rose to 111.1 million from 65.9 million.

Analysis — what it means for biotech investors

The per-share narrowing is the mechanical result of a much larger share count, not improved profitability. Investors tracking dilution should weigh the equity build against the runway extension: the cash position now carries the company into the first half of 2029, past the expected second-half 2027 topline readout.

The restructuring charge is the clearest signal of capital discipline. Aura cut headcount and other costs to concentrate spending on ocular oncology, and the $4.5 million charge lands entirely in this quarter, meaning the run-rate benefit shows up in later periods.

The CDMO relationship matters for a different reason. Designated manufacturing capacity gives Aura long-term control over production scheduling, Chief Operating Officer Susan Abu-Absi said, which is a commercial-readiness step rather than a clinical one. Viral vector manufacturing is a known bottleneck for biologics, and securing capacity before a potential approval reduces execution risk.

The counter-argument is timing. Topline data is not expected until the second half of 2027, and the primary endpoint reads at 15 months even though follow-up runs 24 months. Any delay pushes revenue further out, and the company has no approved product and no product revenue.

Positioning reflects that binary setup. Clinical-stage biotech holders tend to be long the catalyst and short the timeline, and the stock's reaction will hinge on CoMpass execution rather than the quarterly loss.

Outlook — what to watch next

Aura will host an early choroidal melanoma investor and analyst virtual event on December 8, 2026, from 7:30 to 9:00 a.m. ET, featuring Dr. Arun Singh, Director of the Department of Ophthalmic Oncology at the Cole Eye Institute of the Cleveland Clinic. The event will address the current treatment paradigm, unmet need and an updated epidemiology analysis.

CEO Natalie Holles will participate in the Stifel 2026 Healthcare Conference on November 10, 2026, with a fireside chat at 2:40 p.m. ET, and the 9th Annual Evercore Healthcare Conference on December 1, 2026, with a fireside chat at 2:10 p.m. ET. Webcasts will be archived for 90 days.

In the first quarter of 2027, Aura expects to update both its early clinical programs, metastases to the choroid and cancers of the ocular surface, including disease burden, trial design and timelines to future data readouts.

Frequently Asked Questions

What does Aura Biosciences' $32.1 million quarterly loss mean for retail investors?

The loss reflects spending on the Phase 3 CoMpass trial plus a $4.5 million restructuring charge, not a revenue shortfall, since Aura has no approved product. The more relevant figure is the $297.2 million in cash and securities, which the company said funds operations into the first half of 2029, past the expected second-half 2027 topline data.

What happens next for Aura Biosciences and bel-sar?

All 108 CoMpass participants have finished treatment and entered a 24-month follow-up period. Topline data from the 15-month primary endpoint is expected in the second half of 2027. The trial runs under an FDA Special Protocol Assessment, and a successful result would support a potential Biologics License Application.

Why did Aura's general and administrative expenses jump to $10.3 million?

The increase from $5.7 million a year earlier was driven primarily by restructuring charges recognized during the third quarter of 2026. Those charges included employee termination benefits, severance, continued health care coverage, outplacement services and accelerated stock-based compensation. The restructuring plan was completed in the quarter.

Bottom Line

Aura's wider quarterly loss is a spending story, and its $297.2 million cash position carries the bel-sar program past the 2027 topline readout.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.